Epidemiology, Prevalence, and Incidence in Central Retinal Vein Occlusion and Macular Edema

2019 ◽  
pp. 2-4
Keyword(s):  
General Population ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Visual Loss ◽  
Retinal Ischemia ◽  
Common Cause ◽  
Vein Occlusion ◽  
Common Causes ◽  
Central Retinal Vein

Retinal vein occlusion (RVO) is one of the most common causes of acquired retinal vascular anomalies in adults and is a common cause of visual loss. There is little data on the prevalence of RVO in the general population, although it is at least as early as 1855 and there are more than 3000 publications. The number of studies on the incidence of RVO is relatively small. Reduced vision in patients affected by RVO can result from retinal ischemia and/or accumulation of fluid in the center of the retina (macular edema). In this review, studies on epidemiology, prevalence, and incidence in central retinal vein occlusion and macular edema were summarized and evaluated.

scholarly journals Clinical Diagnosis and Classification in Central Retinal Vein Occlusion and Macular Edema

2019 ◽  
pp. 16-20
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Visual Loss ◽  
Vision Loss ◽  
Daily Practice ◽  
Clinical Evaluations ◽  
Vein Occlusion ◽  
Diagnosis And Classification ◽  
Central Retinal Vein

Central retinal vein occlusion (CRVO) is a common and dramatic cause of sudden, painless, and unilateral visual loss. The vast majority of vision loss associated with CRVO results from the macular edema and neovascularization. The diagnosis is generally based upon the history and fundus examination. Common clinical evaluations include fluorescein angiography (FA) and optical coherence tomography (OCT). According to retinal perfusion status, CRVO is classified into two clinical types, and it is important to differentiate between the more common nonischemic type and the less common ischemic type. It is possible to detect the peripheral ischemic areas with wide-angle FA, while the perfusion status of the macula is evaluated by OCT angiography, which takes place in our daily practice.

scholarly journals Epidemiology, Prevalence and Incidence in Branch Retinal Vein Occlusion and Macular Edema

2019 ◽  
pp. 65-67
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Older Patients ◽  
Visual Loss ◽  
Retinal Ischemia ◽  
Vein Occlusion ◽  
Retinal Vascular Disease ◽  
Central Retinal Vein

Retinal vein occlusion (RVO) is the second most common retinal vascular disease after diabetic retinopathy. RVO exists in two subtypes: CRVO (central retinal vein occlusion), which is less common and represents occlusion of the central retinal vein, and BRVO (branch retinal vein occlusion), which is 4-6 times more common and represents occlusion of some branches of central retinal vein. RVO is a relatively common and frequently devastating cause of visual loss mainly in older patients. Its prevalence varies according to studies in overall populations from 5.2 to 16 per 1000. Visual acuity is primarily decreased due to macular edema and retinal ischemia.

Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study

2014 ◽  
Vol 158 (5) ◽  
pp. 1032-1038.e2 ◽  
Author(s):  
Yuichiro Ogura ◽  
Johann Roider ◽  
Jean-François Korobelnik ◽  
Frank G. Holz ◽  
Christian Simader ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Phase 3 ◽  
Vein Occlusion ◽  
Intravitreal Aflibercept ◽  
Central Retinal Vein

scholarly journals The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma after Central Retinal Vein Occlusion: A Retrospective Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Christina L. Ryu ◽  
Adrian Elfersy ◽  
Uday Desai ◽  
Thomas Hessburg ◽  
Paul Edwards ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Significant Risk ◽  
Case Series ◽  
Neovascular Glaucoma ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Purpose. Ischemic central retinal vein occlusion (CRVO) eyes are at high risk of developing neovascular glaucoma (NVG). Our purpose is to investigate the effect of anti-VEGF therapy for macular edema after CRVO on the development of neovascular glaucoma (NVG) in ischemic CRVO eyes.Methods. This is a retrospective case series of 44 eyes from 44 patients with CRVO treated with anti-VEGF therapy for macular edema. The primary outcome was the development of NVG.Results. Of the 44 eyes, 14 eyes had ischemic CRVO, and 30 eyes had nonischemic CRVO. Nonischemic eyes received a mean of 8.4 anti-VEGF doses, over mean follow-up of 24 months. One nonischemic eye (3.3%) developed NVD but not NVG. The 14 ischemic eyes received a mean of 5.6 anti-VEGF doses, with mean follow-up of 23 months. Of these 14 ischemic eyes, two eyes (14%) developed iris neovascularization and 3 eyes (21%) developed posterior neovascularization. Three of these 5 eyes with neovascularization progressed to NVG, at 19.7 months after symptom onset, on average.Conclusion. Anti-VEGF therapy for macular edema may delay, but does not prevent, the development of ocular NV in ischemic CRVO. Significant risk of NVG still exists for ischemic CRVO eyes.

Sign in / Sign up

Export Citation Format

Share Document